Valosin-containing protein and neurofibromin interact to regulate dendritic spine density.

Inclusion body myopathy with Paget disease of bone and frontotemporal dementia (IBMPFD) is an autosomal dominant disorder characterized by progressive myopathy that is often accompanied by bone weakening and/or frontotemporal dementia. Although it is known to be caused by mutations in the gene encoding valosin-containing protein (VCP), the underlying disease mechanism remains elusive. Like IBMPFD, neurofibromatosis type 1 (NF1) is an autosomal dominant disorder. Neurofibromin, the protein encoded by the NF1 gene, has been shown to regulate synaptogenesis. Here, we show that neurofibromin and VCP interact and work together to control the density of dendritic spines. Certain mutations identified in IBMPFD and NF1 patients reduced the interaction between VCP and neurofibromin and impaired spinogenesis. The functions of neurofibromin and VCP in spinogenesis were shown to correlate with the learning disability and dementia phenotypes seen in patients with IBMPFD. Consistent with the previous finding that treatment with a statin rescues behavioral defects in Nf1(+/-) mice and providing further support for our hypothesis that there is crosstalk between neurofibromin and VCP, statin exposure neutralized the effect of VCP knockdown on spinogenesis in cultured hippocampal neurons. The data presented here demonstrate that there is a link between IBMPFD and NF1 and indicate a role for VCP in synapse formation.

[1]  Jeffrey E. Swensen,et al.  Bone resorption in syndromes of the Ras/MAPK pathway , 2011, Clinical genetics.

[2]  Yingze Zhang,et al.  Primary osteopathy of vertebrae in a neurofibromatosis type 1 murine model. , 2011, Bone.

[3]  J. Carey,et al.  Multiple increased osteoclast functions in individuals with neurofibromatosis type 1 , 2011, American journal of medical genetics. Part A.

[4]  P. Robinson,et al.  Neurofibromin (Nf1) is required for skeletal muscle development. , 2011, Human molecular genetics.

[5]  Y. Jan,et al.  Neuronal remodeling and apoptosis require VCP-dependent degradation of the apoptosis inhibitor DIAP1 , 2011, Development.

[6]  Patrizia Sola,et al.  Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2011, Neuron.

[7]  Sonja W. Scholz,et al.  Exome Sequencing Reveals VCP Mutations as a Cause of Familial ALS , 2010, Neuron.

[8]  D. Wallace,et al.  VCP Associated Inclusion Body Myopathy and Paget Disease of Bone Knock-In Mouse Model Exhibits Tissue Pathology Typical of Human Disease , 2010, PloS one.

[9]  B. Blot,et al.  CHMP2B mutants linked to frontotemporal dementia impair maturation of dendritic spines , 2010, Journal of Cell Science.

[10]  H. Vinters,et al.  Synapse loss in dementias , 2010, Journal of neuroscience research.

[11]  L. Esser,et al.  A novel ATP‐dependent conformation in p97 N–D1 fragment revealed by crystal structures of disease‐related mutants , 2010, The EMBO journal.

[12]  A. Wright,et al.  Transgenic mice expressing mutant forms VCP/p97 recapitulate the full spectrum of IBMPFD including degeneration in muscle, brain and bone. , 2010, Human molecular genetics.

[13]  Richard G. W. Anderson,et al.  Sterol-induced Dislocation of 3-Hydroxy-3-methylglutaryl Coenzyme A Reductase from Endoplasmic Reticulum Membranes into the Cytosol through a Subcellular Compartment Resembling Lipid Droplets , 2010, The Journal of Biological Chemistry.

[14]  J. Taylor,et al.  VCP/p97 is essential for maturation of ubiquitin-containing autophagosomes and this function is impaired by mutations that cause IBMPFD , 2010, Autophagy.

[15]  J. Ju,et al.  p97/VCP at the intersection of the autophagy and the ubiquitin proteasome system , 2010, Autophagy.

[16]  J. Nyman,et al.  Local Low-Dose Lovastatin Delivery Improves the Bone-Healing Defect Caused by Nf1 Loss of Function in Osteoblasts , 2010, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[17]  M. Volta,et al.  Characterisation of the interaction between syndecan-2, neurofibromin and CASK: dependence of interaction on syndecan dimerization. , 2010, Biochemical and biophysical research communications.

[18]  D. Piwnica-Worms,et al.  Valosin-containing protein (VCP) is required for autophagy and is disrupted in VCP disease , 2009, The Journal of cell biology.

[19]  V. Golubovskaya,et al.  Neurofibromin physically interacts with the N‐terminal domain of focal adhesion kinase , 2009, Molecular carcinogenesis.

[20]  D. Harats,et al.  Dislocation of HMG-CoA reductase and Insig-1, two polytopic endoplasmic reticulum proteins, en route to proteasomal degradation. , 2009, Molecular biology of the cell.

[21]  M. Latterich,et al.  Hereditary Inclusion Body Myopathy-Linked p97/VCP Mutations in the NH2 Domain and the D1 Ring Modulate p97/VCP ATPase Activity and D2 Ring Conformation , 2009, Molecular and Cellular Biology.

[22]  F. Gao,et al.  ESCRT, autophagy, and frontotemporal dementia. , 2008, BMB reports.

[23]  N. Vij AAA ATPase p97/VCP: cellular functions, disease and therapeutic potential , 2008, Journal of cellular and molecular medicine.

[24]  S. Mundlos,et al.  Modelling neurofibromatosis type 1 tibial dysplasia and its treatment with lovastatin , 2008, BMC medicine.

[25]  Alcino J. Silva,et al.  Effect of Simvastatin on Cognitive Functioning in Children with Neurofibromatosis Type 1 a Randomized Controlled Trial , 2022 .

[26]  Yi-Ling Lin,et al.  SUMOylation of the MAGUK protein CASK regulates dendritic spinogenesis , 2008, The Journal of cell biology.

[27]  J. Hell,et al.  NS21: Re-defined and modified supplement B27 for neuronal cultures , 2008, Journal of Neuroscience Methods.

[28]  Yi-Ling Lin,et al.  Neurofibromin interacts with CRMP-2 and CRMP-4 in rat brain. , 2008, Biochemical and biophysical research communications.

[29]  H. Saya,et al.  Neurofibromatosis Type 1 (NF1) Tumor Suppressor, Neurofibromin, Regulates the Neuronal Differentiation of PC12 Cells via Its Associating Protein, CRMP-2* , 2008, Journal of Biological Chemistry.

[30]  Charles D. Smith,et al.  Clinical studies in familial VCP myopathy associated with Paget disease of bone and frontotemporal dementia , 2008, American journal of medical genetics. Part A.

[31]  L. Parada,et al.  Neurofibromin Is Required for Barrel Formation in the Mouse Somatosensory Cortex , 2008, The Journal of Neuroscience.

[32]  A. Kakizuka Roles of VCP in human neurodegenerative disorders. , 2008, Biochemical Society transactions.

[33]  O. Bugiani The many ways to frontotemporal degeneration and beyond , 2007, Neurological Sciences.

[34]  S. Young,et al.  ESCRT-III Dysfunction Causes Autophagosome Accumulation and Neurodegeneration , 2007, Current Biology.

[35]  Liang Ge,et al.  Ufd1 is a cofactor of gp78 and plays a key role in cholesterol metabolism by regulating the stability of HMG-CoA reductase. , 2007, Cell metabolism.

[36]  A. Kakizuka,et al.  Involvement of valosin‐containing protein (VCP)/p97 in the formation and clearance of abnormal protein aggregates , 2007, Genes to cells : devoted to molecular & cellular mechanisms.

[37]  Yi-Ling Lin,et al.  Syndecan-2 induces filopodia and dendritic spine formation via the neurofibromin–PKA–Ena/VASP pathway , 2007, The Journal of cell biology.

[38]  D. Stephenson,et al.  Recent developments in neurofibromatosis type 1 , 2007, Current opinion in neurology.

[39]  Hiderou Yoshida,et al.  ER stress and diseases , 2007, The FEBS journal.

[40]  K. Talbot,et al.  Recent advances in the genetics of amyotrophic lateral sclerosis and frontotemporal dementia: common pathways in neurodegenerative disease. , 2006, Human molecular genetics.

[41]  W. Hwu,et al.  Identification of forty‐five novel and twenty‐three known NF1 mutations in Chinese patients with neurofibromatosis type 1 , 2006, Human mutation.

[42]  V. Rybin,et al.  HDAC6–p97/VCP controlled polyubiquitin chain turnover , 2006, The EMBO journal.

[43]  Charles D. Smith,et al.  Novel Ubiquitin Neuropathology in Frontotemporal Dementia With Valosin-Containing Protein Gene Mutations , 2006, Journal of neuropathology and experimental neurology.

[44]  Yinghua Zhu,et al.  Effect of neurofibromatosis type I mutations on a novel pathway for adenylyl cyclase activation requiring neurofibromin and Ras. , 2006, Human molecular genetics.

[45]  W. Westbroek,et al.  Neurofibromatosis type 1 protein and amyloid precursor protein interact in normal human melanocytes and colocalize with melanosomes. , 2006, The Journal of investigative dermatology.

[46]  J. Tonsgard Clinical manifestations and management of neurofibromatosis type 1. , 2006, Seminars in pediatric neurology.

[47]  M. Sheng,et al.  Molecular mechanisms of dendritic spine morphogenesis , 2006, Current Opinion in Neurobiology.

[48]  S. Dalal,et al.  Inclusion body myopathy-associated mutations in p97/VCP impair endoplasmic reticulum-associated degradation. , 2006, Human molecular genetics.

[49]  G. Skibinski Mutations in the ESCRTIII endosomal complex protein CHMP2B associate with frontotemporal dementia , 2005 .

[50]  Alcino J. Silva,et al.  The HMG-CoA Reductase Inhibitor Lovastatin Reverses the Learning and Attention Deficits in a Mouse Model of Neurofibromatosis Type 1 , 2005, Current Biology.

[51]  A. Dunaevsky,et al.  Dendritic spine morphogenesis and plasticity. , 2005, Journal of neurobiology.

[52]  Mary B. Kennedy,et al.  Spine architecture and synaptic plasticity , 2005, Trends in Neurosciences.

[53]  K. Fliessbach,et al.  Mutant valosin‐containing protein causes a novel type of frontotemporal dementia , 2005, Annals of neurology.

[54]  Elena B. Pasquale,et al.  Molecular mechanisms of dendritic spine development and remodeling , 2005, Progress in Neurobiology.

[55]  H. Kondo,et al.  p97/p47-Mediated biogenesis of Golgi and ER. , 2005, Journal of biochemistry.

[56]  Nobumasa Kato,et al.  Association between the neurofibromatosis‐1 (NF1) locus and autism in the Japanese population , 2004, American journal of medical genetics. Part B, Neuropsychiatric genetics : the official publication of the International Society of Psychiatric Genetics.

[57]  Changcheng Song,et al.  Molecular perspectives on p97-VCP: progress in understanding its structure and diverse biological functions. , 2004, Journal of structural biology.

[58]  A. Pestronk,et al.  Inclusion body myopathy associated with Paget disease of bone and frontotemporal dementia is caused by mutant valosin-containing protein , 2004, Nature Genetics.

[59]  Hisao Kondo,et al.  Structural basis of the interaction between the AAA ATPase p97/VCP and its adaptor protein p47 , 2004, The EMBO journal.

[60]  H. Saya,et al.  PKA phosphorylation and 14‐3‐3 interaction regulate the function of neurofibromatosis type I tumor suppressor, neurofibromin , 2004, FEBS letters.

[61]  B. Delabarre,et al.  NSF and p97/VCP: similar at first, different at last , 2003, FEBS letters.

[62]  P. Woodman p97, a protein coping with multiple identities , 2003, Journal of Cell Science.

[63]  K. Okamoto,et al.  Vacuole-creating protein in neurodegenerative diseases in humans , 2003, Neuroscience Letters.

[64]  Heike Hering,et al.  Lipid Rafts in the Maintenance of Synapses, Dendritic Spines, and Surface AMPA Receptor Stability , 2003, The Journal of Neuroscience.

[65]  A. May,et al.  Conformational changes of the multifunction p97 AAA ATPase during its ATPase cycle , 2002, Nature Structural Biology.

[66]  C. Taxis,et al.  Protein dislocation from the ER requires polyubiquitination and the AAA-ATPase Cdc48 , 2002, Nature Cell Biology.

[67]  Alcino J. Silva,et al.  Mechanism for the learning deficits in a mouse model of neurofibromatosis type 1 , 2002, Nature.

[68]  M. Sheng,et al.  Dentritic spines : structure, dynamics and regulation , 2001, Nature Reviews Neuroscience.

[69]  K. Tanaka,et al.  VCP/p97 in abnormal protein aggregates, cytoplasmic vacuoles, and cell death, phenotypes relevant to neurodegeneration , 2001, Cell Death and Differentiation.

[70]  Chou-Chi H. Li,et al.  Valosin-containing protein is a multi-ubiquitin chain-targeting factor required in ubiquitin–proteasome degradation , 2001, Nature Cell Biology.

[71]  E. Bigio,et al.  Contribution of asymmetric synapse loss to lateralizing clinical deficits in frontotemporal dementias. , 2001, Archives of neurology.

[72]  N. Loberto,et al.  Changes in the Lipid Turnover, Composition, and Organization, as Sphingolipid-enriched Membrane Domains, in Rat Cerebellar Granule Cells Developing in Vitro * , 2001, The Journal of Biological Chemistry.

[73]  M. Sheng,et al.  Bipartite Interaction between Neurofibromatosis Type I Protein (Neurofibromin) and Syndecan Transmembrane Heparan Sulfate Proteoglycans , 2001, The Journal of Neuroscience.

[74]  H. Saya,et al.  Phosphorylation of neurofibromin by cAMP‐dependent protein kinase is regulated via a cellular association of N G,N G‐dimethylarginine dimethylaminohydrolase , 2001, FEBS letters.

[75]  L. Parada,et al.  Neurofibromin, a tumor suppressor in the nervous system. , 2001, Experimental cell research.

[76]  T. Jacks,et al.  NF1 Tumor Suppressor Gene Function Narrowing the GAP , 2001, Cell.

[77]  D. Vidaud,et al.  NF1 gene analysis focused on CpG‐rich exons in a cohort of 93 patients with neurofibromatosis type 1 , 2000, Human mutation.

[78]  G Mortier,et al.  Exhaustive mutation analysis of the NF1 gene allows identification of 95% of mutations and reveals a high frequency of unusual splicing defects , 2000, Human mutation.

[79]  M. Sheng,et al.  Nuclear translocation and transcription regulation by the membrane-associated guanylate kinase CASK/LIN-2 , 2000, Nature.

[80]  C. Barthélémy,et al.  Association study of the NF1 gene and autistic disorder. , 1999, American journal of medical genetics.

[81]  A. Crawford,et al.  Neurofibromatosis in children: the role of the orthopaedist. , 1999, The Journal of the American Academy of Orthopaedic Surgeons.

[82]  B. Miller,et al.  Frontotemporal dementia: Neuropil spheroids and presynaptic terminal degeneration , 1998, Annals of neurology.

[83]  D. Longo,et al.  Involvement of Valosin-containing Protein, an ATPase Co-purified with IκBα and 26 S Proteasome, in Ubiquitin-Proteasome-mediated Degradation of IκBα* , 1998, The Journal of Biological Chemistry.

[84]  D. Longo,et al.  Involvement of valosin-containing protein, an ATPase Co-purified with IkappaBalpha and 26 S proteasome, in ubiquitin-proteasome-mediated degradation of IkappaBalpha. , 1998, The Journal of biological chemistry.

[85]  A. Brun,et al.  Cortical synaptic changes and gliosis in normal aging, Alzheimer's disease and frontal lobe degeneration. , 1996, Dementia.

[86]  Robert A. Weinberg,et al.  Tumour predisposition in mice heterozygous for a targeted mutation in Nf1 , 1994, Nature Genetics.

[87]  D. Price,et al.  Synapse loss in the temporal lobe in Alzheimer's disease , 1993, Annals of neurology.

[88]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[89]  S. Sebti,et al.  Lovastatin, a cholesterol biosynthesis inhibitor, inhibits the growth of human H-ras oncogene transformed cells in nude mice. , 1991, Cancer communications.

[90]  J. Backer,et al.  Lovastatin blocks N-ras oncogene-induced neuronal differentiation. , 1990, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[91]  B. Brownstein,et al.  Type 1 neurofibromatosis gene: identification of a large transcript disrupted in three NF1 patients. , 1990, Science.

[92]  P. O'Connell,et al.  Deletions and a translocation interrupt a cloned gene at the neurofibromatosis type 1 locus , 1990, Cell.

[93]  P. O'Connell,et al.  A major segment of the neurofibromatosis type 1 gene: cDNA sequence, genomic structure, and point mutations , 1990, Cell.

[94]  S. DeKosky,et al.  Synapse loss in frontal cortex biopsies in Alzheimer's disease: Correlation with cognitive severity , 1990, Annals of neurology.

[95]  KM Harris,et al.  Dendritic spines of CA 1 pyramidal cells in the rat hippocampus: serial electron microscopy with reference to their biophysical characteristics , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[96]  P. Greengard,et al.  Synapsin I (protein I), a nerve terminal-specific phosphoprotein. III. Its association with synaptic vesicles studied in a highly purified synaptic vesicle preparation , 1983, The Journal of cell biology.